Biota Holdings reports Relenza sales, indicative royalties for three months ended 31 December 2009

Download PDF Copy

Feb 5 2010

NewsGuard 100/100 Score

Holdings Limited (ASX:BTA) today announced that it had received written notification from GlaxoSmithKline that Relenza sales were $462 million and indicative royalties were $32.6 million, for the three months ended 31 December 2009. The figures were calculated on an Australian dollar exchange rate of 1.8182 to the UK pound, although the actual payment will be calculated on exchange rates at 30 April 2010.

Biota will report first half indicative Relenza royalty income of $56.7 million (2008: $3.8m) when it releases its Interim Report on 17 February 2010.

Source:

Biota Holdings Limited

Posted in:

Tags: GlaxoSmithKline, Hepatitis C, Influenza, Virus

Comments (0)

Download PDF Copy

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.